Aperture Therapeutics is advancing APRTX-003, an RNA-based antisense therapy targeting MMP9, as a potential ALS treatment.

Currently, the MyoRegulator® device is under investigation as a non-invasive treatment for ALS in a second and larger clinical trial, the CALM ( C ontrolling A myotrophic L ateral Sclerosis M otor ...

The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...

A pharmaceutical company based in New Jersey that’s known for its FDA-approved treatment for ALS is set to be acquired for $2.5 billion. Tanabe Pharma America, which operates a U.S. headquarters in ...

According to the ALS Association, most patients of the disease die within five years of diagnosis. Reporting for TODAY, NBC’s Anne Thompson shares a look at a groundbreaking therapy called an ASO that ...

On a quiet farm in Erie County, Pennsylvania, 67-year-old Diane Zaczyk used to think nothing of hefting 50-pound sacks of chicken feed onto her shoulder. Strong, stubborn and devoted to caring for her ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved RELYVRIO™ ...

Essentia Health’s new drug treatment is being administered through their ALS Expanded Access Protocol (EAP). However, it’s a new non-FDA approved drug treatment where their first ever patient with ...

Some evidence reports natural medications, such as Wugongtang and Dihuangyinzi, may help slow the progression of ALS or Lou Gehrig’s disease. However, they cannot cure it. Amyotrophic lateral ...

Six newly Certified Centers join the organization's network of clinics and expand access to multidisciplinary care and research for people living with ALS. ALS, often called Lou Gehrig's disease, is a ...

The preparations for the regulatory submission for early commercialization in Canada follows the positive Phase 2b trial results which show PrimeC reduces ALS disease progression by 36% and improves ...

Inflammasome Therapeutics (https://www.inflam.com), a clinical-stage biotech company developing a new class of drugs, Kamuvudines, for ophthalmic and neurological conditions, announced the company has ...